Biocartis Group NV

Invitation to Annual Shareholders' Meeting

PRESS RELEASE                                                                                     9 April 2019, 07:00 CEST
                                                                                                            REGULATED INFORMATION

Invitation to Annual Shareholders' Meeting

Mechelen, Belgium, 9 April 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, warrant holders, directors and statutory auditor to its annual shareholders' meeting that will be held on Friday 10 May 2019 at 2:00 p.m. CEST ('AGM') at the offices of the Company at Generaal de Wittelaan 11B, 2800 Mechelen, Belgium. 

In order to be admitted to the AGM, the holders of securities issued by the Company must comply with Article 536 of the Belgian Companies Code and the articles of association of the Company, and fulfill the formalities described in the convening notice. The convening notice and other documents relating to the AGM can be consulted on the website of the Company.

--- END ---

More information:

Renate Degrave
Manager Corporate Communications & Investor Relations
e-mail   [e-mail]
tel         [phone]
gsm      [phone]
@Biocartis_
www.linkedin.com/Biocartis

About Biocartis 

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology. This area represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.